Kagami-Ogata syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:254519OMIM:608149Q87.8
Who is this for?
Show terms as
1Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Kagami-Ogata syndrome (KOS), also known as paternal uniparental disomy of chromosome 14 (UPD(14)pat) syndrome, is a rare imprinting disorder caused by overexpression of paternally expressed genes and loss of maternally expressed genes in the chromosome 14q32 imprinted region. The underlying molecular mechanisms include paternal uniparental disomy of chromosome 14, microdeletions of the maternal differentially methylated region (DMR), or epimutations (hypermethylation) at the MEG3/DLK1 intergenic DMR. The condition is characterized by distinctive features that are apparent from the prenatal and neonatal periods. Key clinical features include a characteristic facial appearance with full cheeks, a depressed nasal bridge, a short nose with anteverted nares, and a protruding philtrum. Affected individuals typically present with a bell-shaped thorax with coat-hanger appearance of the ribs, abdominal wall defects (omphalocele or diastasis recti), polyhydramnios, and placentomegaly during the prenatal period. Severe respiratory difficulties at birth are common due to the small, bell-shaped thorax and may be life-threatening in the neonatal period. Hepatoblastoma is a recognized complication, and developmental delay of variable degree is frequently observed. Joint contractures, particularly of the fingers, and feeding difficulties are also commonly reported. There is no specific curative treatment for Kagami-Ogata syndrome. Management is supportive and multidisciplinary, focusing on respiratory support in the neonatal period (which may require mechanical ventilation), surgical correction of abdominal wall defects, nutritional support for feeding difficulties, and developmental therapies. Surveillance for hepatoblastoma with regular abdominal ultrasound and alpha-fetoprotein monitoring is recommended. With appropriate neonatal intensive care, survival beyond the critical neonatal period has improved, though long-term outcomes vary depending on the severity of thoracic and respiratory involvement.

Also known as:

Clinical phenotype terms— hover any for plain English:

Broad philtrumHP:0000289Bell-shaped thoraxHP:0001591Respiratory failure requiring assisted ventilationHP:0004887Thoracic hypoplasiaHP:0005257Large placentaHP:0006267Coat hanger sign of ribsHP:0006665
Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Kagami-Ogata syndrome.

View clinical trials →

No actively recruiting trials found for Kagami-Ogata syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Kagami-Ogata syndrome community →

Specialists

1 foundView all specialists →

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Kagami-Ogata syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Kagami-Ogata syndromeForum →

No community posts yet. Be the first to share your experience with Kagami-Ogata syndrome.

Start the conversation →

Latest news about Kagami-Ogata syndrome

No recent news articles for Kagami-Ogata syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Kagami-Ogata syndrome

What is Kagami-Ogata syndrome?

Kagami-Ogata syndrome (KOS), also known as paternal uniparental disomy of chromosome 14 (UPD(14)pat) syndrome, is a rare imprinting disorder caused by overexpression of paternally expressed genes and loss of maternally expressed genes in the chromosome 14q32 imprinted region. The underlying molecular mechanisms include paternal uniparental disomy of chromosome 14, microdeletions of the maternal differentially methylated region (DMR), or epimutations (hypermethylation) at the MEG3/DLK1 intergenic DMR. The condition is characterized by distinctive features that are apparent from the prenatal and

At what age does Kagami-Ogata syndrome typically begin?

Typical onset of Kagami-Ogata syndrome is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Kagami-Ogata syndrome?

1 specialists and care centers treating Kagami-Ogata syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.